Practical Tips

Spasticity in multiple sclerosis and cannabinoid receptors: what CB1 does, what CB2 does, how nabiximols works, and what clinical studies have really shown about it.

We check what has really been measured regarding cannabidiol, the TRPV2 receptor, and the cleaning of amyloid by microglia. Three works, three different research objects.

What studies show about the inhibition of the FAAH enzyme: Cravatt's mice, lack of inhibition of the human enzyme by cannabidiol, and the disaster of the BIA 10-2474 drug.

Does CBD protect the brain after a stroke? What have animal models of ischemia really shown, where the limits of preclinical data lie, and what does the clinical trial registry say.

CBD, reperfusion arrhythmia, and the CB1 receptor: what has been shown in animal models, why the attributed mechanism is questionable, and what are the interactions with drugs.

The entire basis for CBD in diabetic cardiomyopathy is one experiment on type 1 diabetic mice. What was measured, by what method, and what is missing in this work.

CBD in schizophrenia: what the Leweke 2012 and McGuire 2018 studies showed, how the inhibition of anandamide breakdown works, and why it is not a substitute for treatment.

Why pre-chemotherapy nausea escapes serotonin antagonists and what preclinical studies show about cannabinoids. The CB1 and 5-HT1A mechanism without simplifications.

The inverted U curve in Zuardi's study, the published protocol for slow titration involving Dr. Sulak, and the provisional safe dose EFSA 2026.

A one-hitter is one of the smallest pipes in use. How much does one portion hold, what is it made of, how to clean it, and does it really save material.